Clinical trials: Non-epileptic Seizures
- Condition Non-epileptic Seizures
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Epilepsies, Partial
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].
- Trial name
- NCT00367432
- Testing
- Levetiracetam
- Where
- 53 sites in Japan
- Volunteers
- 398 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
Seizure Prediction Using Wearable EEG
This study is a non-interventional clinical trial analyzing EEG recordings from people with epilepsy. Participants wear a comfortable EEG headband at home for several weeks.
- Trial name
- NCT06978842
- Testing
- Wearable EEG headband for passive brain signal acquisition
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Dux Healthcare Inc.
Status Epilepticus, Convulsive Status EPILEPTICUS
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
- Conditions
- Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy
- Trial name
- NCT03350035
- Testing
- IV Ganaxolone active
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Dravet Syndrome
Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA
The present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of Dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on…
- Trial name
- NCT05544058
- Testing
- Retrospective study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Biocodex
STXBP1 Encephalopathy with Epilepsy
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
This is a prospective, non-interventional, longitudinal study designed to characterize the natural history of STXBP1 related encephalopathy with epilepsy, in participants ≤ <5 years of age.
- Trial name
- NCT05462054
- Sponsor
- Capsida Biotherapeutics, Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy With Simple or Complex Partial Onset Seizures
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT00866775
- Testing
- Eslicarbazepine acetate
- Where
- 106 sites in United States, Canada
- Volunteers
- 193 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Epilepsy, Tonic-Clonic
EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System
To demonstrate the safety and effectiveness of the EpiWatch device in identifying tonic-clonic (TC) seizures, notifying a third-party of TC seizure occurrence, and collecting non-EEG physiological data for subsequent review…
- Trial name
- NCT05059002
- Testing
- Physiological signal monitoring and seizure detection
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- EpiWatch, Inc.
Epilepsy
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT01091662
- Testing
- Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
- Where
- 62 sites in United States, Bulgaria and 3 more
- Volunteers
- 172 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
Tonicity Monitor For Epilepsy and Hypertonic Disorders
Epilepsy is an episodic disorder which can result in recurrent seizures often associated with hypertonia (muscle stiffening) and myoclonia (involuntary muscle jerking).
- Trial name
- NCT02110589
- Testing
- Epidetect
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vikel Ltd
Infantile Spasms
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug.
- Trial name
- SoluWest (NCT02220114)
- Testing
- Vigabatrin: Vigabatrin new ST formulation then Sabril®
- Where
- 12 sites in France
- Volunteers
- 38 people
- Sponsor
- Orphelia Pharma
Epilepsies, Partial
A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
- Trial name
- NCT00603473
- Testing
- gabapentin
- Where
- 26 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Altered Mental Status, Generalized Nonconvulsive Seizure Disorder
Putting Electroencephalography (EEG) in the Emergency Department
The aim of the proposed research is to compare the diagnostic accuracy of a portable wireless electroencephalography (EEG) device (Biosignal Micro-EEG) to standard EEG in identifying abnormal EEG patterns (mainly non-convulsive…
- Conditions
- Altered Mental Status, Generalized Nonconvulsive Seizure Disorder, Status-epilepticus
- Trial name
- NCT01355211
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- Bio-Signal Group Corp.
Status Epilepticus
Randomized Therapy In Status Epilepticus
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
- Trial name
- RAISE (NCT04391569)
- Testing
- Ganaxolone
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Marinus Pharmaceuticals
KCNT1-Related Epilepsy
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive…
- Trial name
- K1Te (NCT04924153)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Biogen